Trained Neuroscientist Brings Vast Experience in Business Development and Preclinical Research to Accelerate Company Efforts in Developing Next-Generation Psychedelic Medicines TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next…


Previous articlePT291 – Rick Tarnas & Sean Kelly, Ph.D. – The Impact of Stanislav Grof, Ego Death, and The Psyche Unbound
Next articleMYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial